Management of hepatocellular carcinoma

Journal of the Royal College of Surgeons of Edinburgh

Volumn 47, Issue 1, 2002, Pages 389-399

  Lau, W Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatocellular carcinoma; Non surgical treatment; Surgical treatment

Indexed keywords

ALCOHOL; ALPHA INTERFERON; ANDROSTANOLONE; ANTIANDROGEN; ANTIESTROGEN; BETA INTERFERON; CARMOFUR; CHLOROTRIANISENE; CISPLATIN; CYPROTERONE; DOXORUBICIN; EPIRUBICIN; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; IODINATED POPPYSEED OIL; IODINE 131; KETOCONAZOLE; MENOGARIL; MITOMYCIN C; OCTREOTIDE; RADIOISOTOPE; RECOMBINANT ALPHA2 INTERFERON; SODIUM CHLORIDE; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; YTTRIUM 90;

ABDOMINAL DISCOMFORT; ADVANCED CANCER; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CATHETER ABLATION; CHOLANGITIS; CONTROLLED STUDY; EARLY CANCER; FLU LIKE SYNDROME; GENE THERAPY; HEPATIC ARTERY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; PANCREATITIS; PARTIAL HEPATECTOMY; RADIATION INJURY; REVIEW; STOMACH ULCER; SURVIVAL;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS;

EID: 0036176358     PISSN: 00358835     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (143)

1. Neoplasms of the Liver
2. Primary Hepatocellular Carcinoma
3. Primary Liver Tumours
4. The history of liver surgery
5. Hepatocellular carcinoma: Importance of histologic classification as a prognostic factor
6. Primary hepatic malignancy: Surgical management and determinants of survival
7. Therapeutic modalities and prognostic factors for primary and secondary liver tumours
8. Evaluation of 50 consecutive segmental hepatic resections
9. Hepatic resection for hepatocellular carcinoma: An audit of 343 patients
10. Hepatic resection for small hepatocellular carcinoma: The Queen Mary Hospital experience
11. Liver resection for hepatocellular carcinoma in the elderly
12. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment
13. Resection of hepatocellular carcinoma with diaphragmatic invasion
14. Percutaneous portal vein embolisation increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver
15. Preoperative portal vein embolisation improves prognosis after right hepatectomy for hepato-cellular carcinoma in patients with impaired liver function
16. Improved survival with resection after transcatheter arterial chemoembolisation (TACE) for unresectable hepatocellular carcinoma
17. Is preoperative hepatic arterial chemoembolisation safe and effective for hepato-cellular carcinoma?
18. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: Evaluation with analysis of 72 patients
19. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90 yttrium microspheres
20. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma
21. Lack of intrahepatic recurrence of heptocellular carcinoma by temporary portal venous embolisation with starch microspheres
22. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years
23. Resection of hepatocellular carcinoma after transcatheter arterial embolisation: Re-evaluation of the advantages and disadvantages of preoperative embolisation
24. Results of treatment of patients with hepatocellular carcinoma with severe cirrhosis of the liver
25. Primary treatment of hepatocellular carcinoma by arterial chemoembolisation
26. Limited hepatic resection for selected cirrhotic patients with primary liver cancer
27. Postoperative prophylactic lipiodolisation reduces the intrahepatic recurrence of hepatocellular carcinoma
28. The potential role of postoperative hepatic artery chemotheapy in patients with high-risk hepatomas
29. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: A randomized controlled trial
30. Treatment of hepatocellular carcinoma: A systemic review of randomised controlled trials
31. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma
32. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma
33. Multidisciplinary management of hepatocellular carcinoma
34. Adjuvant oral chemotherapy to prevent recurrence after curative resection for heptocellular carcinoma
35. Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma
36. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomized trial
37. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial
38. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients
39. Primary hepatic malignancy: The role of liver transplantation
40. Liver transplantation for hepatocellular carcinoma: Clinical results and future aspects
41. Liver transplantation for hepatocellular carcinoma
42. Hepatic resection versus transplantation for hepatocellular carcinoma
43. Hepatic transplantation for primary and metastatic cancers of the liver
44. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis
45. Experience of orthotopic liver transplantation and hepatic resection for hepatocellular carcinoma of less than 8 cm in patients with cirrhosis
46. Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis. Primary hepatocellular carcinoma is not a predictor for HBV recurrence
47. Discussion on: Hepatic transplantation for primary and metastatic cancers of the liver
48. Discussion on: Hepatic resection versus transplantation for hepatocellular carcinoma
49. Discussion on: Hepatic transplantation for primary and metastatic cancers of the liver
50. Cytoreductive surgery for hepatocellular carcinoma
51. Indications for palliative reduction surgery in advanced hepatocellular carcinoma. The use of a remnant tumor index
52. Place of cryosurgery in the treatment of malignant liver tumors
53. Intralesional ethanol in the treatment of unresectable liver cancer
54. Intraoperative microwave tissue coagulation as tretment for patients with nonresectable hepatocellular carcinoma
55. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study of 22 patients
56. Intratumor ethanol injection therapy for solitary minute hepatocellular carcinoma. A study of 37 patients
57. Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection
58. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients
59. Improved survival with percutaneous ethanol injection in patients with large hepatocellular carcinoma
60. Treatment of large HCC : Transcatheter arterial chemoembolisation combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization
61. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma - An impossible meta-analysis?
62. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma
63. Ultrasound guided internal radiotherapy using yttrium-90 glass microspheres for liver malignancies
64. Sonographically guided microwave coagulation treatment of liver cancer: An experimental and clinical study
65. Sequential percutaneous microwave coagulation therapy for liver tumor
66. Percutaneous microwave coagulation therapy in liver tumors. A 3-year experience
67. Preliminary clinical experience with laser-induced interstitial thermotherapy in patients with hepatocellular carcinoma
68. Malignant liver tumours treated with MR imaging-guided laser-induced thermotherapy. Techniques and prospective results
69. Clinical results of radio frequency hypertermia for malignant liver tumors
70. Percutaneous ultrasound-guided radiofrequency electro-cautery for the treatment of small hepatocellular carcinoma
71. Treatment of malignant tumours using percutaneous hot saline injection feasibility study and preliminary results
72. Percutaneous hot saline injection therapy for hepatic tumours: An alternative to percutaneous ethanol injection therapy
73. Percutaneous hyperthermic distilled water injection therapy (PHDT) for liver cancer
74. Increased risk of tumour seeding after percutaneous radio frequency ablation of single hepato-cellular carcinoma
75. Techniques and therapies for primary and metastatic liver cancer
76. The surgical management of primary carcinoma of the liver
77. Results of surgical treatments of primary hepatocellular carcinoma: Some aspects to improve long-term survival
78. Collateral arterial blood supply of the liver after hepatic artery ligation. Angiographic study of 20 patients
79. Treatment of unresectable hepatocellular carcinoma: Results of a randomized controlled trial
80. Transarterial embolisation versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized controlled trial in a single institution
81. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma-a randomized controlled trial
82. Hepatic artery embolization in the treatment of hepatic malignancies
83. The role of hepatic arterial embolisation in the management of ruptured hepatocellular carcinoma
84. Experimental studies on the circulatory dynamics of intrahepatic blood flow supply
85. The blood supply of neoplasms in the liver
86. Methods to enhance the efficacy of regional chemotherapeutic treatment of liver malignancies
87. Clinical pharmacokinetics of intraarterial cisplatin in humans
88. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: Effect of coadministration of lipiodol
89. Hepatic arterial infusion of fluorouridine, leucovorin, doxorubicin and cisplatin for hepatocellular carcinoma: Effects of hepatitis B and C viral infection on drug toxicity and patient survival
90. Aggressive treatment for advanced hepatocellular carcinoma (HCC). High response rate and prolonged survival
91. Hepatic artery infusion (HAI) with 5-FUDR, adriamycin (A) and streptozotocin (St) in unresectable hepatoma
92. Selective and persistent deposition and gradual drainage of iodized oil, Lipiodol in the hepatocellular carcinoma after injection into the feeding hepatic artery
93. Hepatocellular carcinoma detected by iodized oil
94. Chemoembolisation with lipiodol and doxorubicin: Applicability in British patients with hepatocellular carcinoma
95. Prolonged survival with chemotherapy alone for hepatocellular carcinoma (HCC) with intra-arterial chemotherapy
96. A 5-year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma
97. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma
98. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: A preliminary report
99. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment of hepatoma
100. A randomised trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma
101. Phase II study of intra-hepatic arterial (I/A) cis-platinum, doxorubicin and Spherex for advanced stage hepatocellular carcinoma (HCC)
102. A randomised trial of hepatic arterial chemoembolisation in patients with unresectable hepatocellular carcinoma
103. Chemoembolisation for hepatocellular carcinoma
104. Hepatic arterial embolisation in patients with unresectable hepatocellular carcinoma. A randomised controlled trial
105. A prospective randomised evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolisation
106. Transcatheter arterial chemoembolisation in inoperable hepatocellular carcinoma: Four-year follow-up
107. A comparison of lipiodol chemoembolisation and conservative treatment for unresectable hepatocellular carcinoma
108. Efficacy of chemoembolisation for hepatocellular carcinomas: Experience from the Gustave Roussy Institute and the Bicentre Hospital
109. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolisation
110. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study
111. Prospective and randomised controlled study of chemoembolisation therapy in patients with advanced hepatocellular carcinoma
112. Comparison of the anticancer effect of ADMOS alone and ADMOS with CDDP in the treatment of hepatocellular carcinoma by intra-arterial injection
113. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - A comparison of lipiodol transcatheter arterial embolization with and without adriamycin
114. Nonresectional therapies for hepatocellular carcinoma
115. Improved survival with resection after transcatheter arterial chemoembolisation (TACE) for unresectable hepatocellular carcinoma
116. Dosimetry of iodine-131 ethiodol in the treatment of hepatoma
117. Selective internal radiation therapy with intra-arterial iodine 131-lipiodol in inoperable hepatocellular carcinoma
118. Internal radiation therapy for hepatocellular carcinoma, results of a French multicentre phase II trial of transarterial injection of iodine 131-labeled lipiodol
119. Nodular hepatocellular carcinoma. Treatment with subsegmental intra-arterial injection of iodine 131-labeled iodized oil
120. Ablation of recurrent primary liver cancer using 131 I-Lipiodol
121. Randomised controlled trial for hepatocellular carcinoma with portal vein thrombosis: Intra-arterial iodine-131-iodized oil versus medical support
122. Selective internal radiation (SIR) therapy for treatment of liver metastases: Measurement of response rate
123. Glass yttrium-90 microspheres for patients with colorectal liver metastases
124. Hepatocellular carcinoma: Pilot trial of treatment with Y-90 microspheres
125. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma
126. Clinical trials in primary hepatocellular carcinoma: Current status and future directions
127. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomised trial
128. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: A prospective randomised trial
129. Recombinant interferon-alpha in inoperable hepatocellular cellular carcinoma: A randomized controlled trial
130. Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menogaril
131. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
132. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomised, controlled trial
133. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma
134. Prospective controlled trial with anti-estrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma
135. Traitment du carcinome hepato-cellulaire par le tamoxifene. Gastroenterology
136. Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients
137. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma
138. Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma
139. Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone
140. Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study
141. Octreotide in hepatocellular carcinoma
142. Gene therapy for primary and metastatic cancer to the liver
143. Hospice Care